{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:40:38Z","timestamp":1777102838737,"version":"3.51.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Bendamustine was approved for treating chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Despite its therapeutic benefits, the long-term safety of bendamustine in a large population remains inadequately understood. This study evaluates the adverse events (AEs) associated with bendamustine, using a real-world pharmacovigilance database to support its clinical application.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a post-marketing risk analysis to assess the association between bendamustine and its AEs. Data were extracted from the US FDA\u2019s Adverse Event Reporting System (FAERS), covering the period from January 2017 to September 2023. The characteristics of bendamustine-associated AEs and the onset time were further analyzed. Statistical analysis was performed using MYSQL 8.0, Navicat Premium 15, Microsoft EXCEL 2016, and Minitab 21.0.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 9,461,874 reports were collected from the FAERS database, 9,131 identified bendamustine as the \u201cprimary suspected\u201d drug. We identified 331 significant disproportionality preferred terms (PTs). Common AEs included pyrexia, neutropenia, infusion site reaction, progressive multifocal leukoencephalopathy (PML), injection site vasculitis, and pneumonia\u2014all documented on bendamustine\u2019s label. Notably, 16 unexpected and significant AEs were discovered, including hypogammaglobulinemia, which is concerning due to its potential to increase infection susceptibility following bendamustine treatment. Other significant findings were anaphylactic reactions, PML, and cutaneous malignancies, suggesting updates to the drug\u2019s label may be necessary. Physicians should monitor for neurological and skin changes in patients and discontinue treatment if PML is suspected. Moreover, the median onset time for bendamustine-associated AEs was 13 days, with an interquartile range [IQR] of 0\u201359 days, predominantly occurring on the first day post-initiation. The \u03b2 of bendamustine-related AEs suggested risk reduction over time.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study uncovered some potential pharmacovigilance signals for bendamustine, providing important insights for its safe and effective clinical use.<\/jats:p>","DOI":"10.3389\/fphar.2024.1372401","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:58:23Z","timestamp":1715576303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Dan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia Qi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan Bing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the food and drug administration adverse event reporting system (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ajh.26895","article-title":"Bendamustine plus rituximab for the treatment of Waldenstr\u00f6m Macroglobulinemia: patient outcomes and impact of bendamustine dosing","volume":"98","author":"Arulogun","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.23822\/EurAnnACI.1764-1489.158","article-title":"Anaphylaxis","volume":"53","author":"Bil\u00f2","year":"2021","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1714\/1988.21524","article-title":"Cardiac involvement in Churg-Strauss syndrome","volume":"16","author":"Brucato","year":"2015","journal-title":"G. Ital. Cardiol. (Rome)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.01.004","article-title":"Reappraisal of primary hepatic lymphoma: is surgical resection underestimated?","volume":"123","author":"Cesaretti","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/ph16070994","article-title":"Is there a risk for semaglutide misuse? Focus on the food and drug administration's FDA adverse events reporting system (FAERS) pharmacovigilance dataset","volume":"16","author":"Chiappini","year":"2023","journal-title":"Pharm. (Basel)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00277-015-2478-9","article-title":"Phase II study of bendamustine combined with rituximab in relapsed\/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings","volume":"94","author":"Czuczman","year":"2015","journal-title":"Ann. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5414\/CN108908","article-title":"Bendamustine-induced nephrogenic diabetes insipidus","volume":"87","author":"Derman","year":"2017","journal-title":"Clin. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/10781552211013878","article-title":"Bendamustine-induced nephrogenic diabetes insipidus - a case report","volume":"28","author":"Desjardins","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e219807","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/cancers15040999","article-title":"Body composition in patients with follicular lymphoma: asso-ciations between changes in radiomic parameters in patients treated with R-CHOP-like and R-B regimens: LyRa 01F","volume":"15","author":"Esposito","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1012093","DOI":"10.3389\/fonc.2022.1012093","article-title":"Platinum drugs-related safety profile: the latest five-year analysis from FDA adverse event reporting system data","volume":"12","author":"Feng","year":"2023","journal-title":"Front. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-Line Treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/cncr.34544","article-title":"Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: an open-label, single-agent, multicenter study in China","volume":"129","author":"Gao","year":"2023","journal-title":"Cancer"},{"key":"B20","unstructured":"Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML)2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1111\/bcp.15711","article-title":"Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: a disproportionality analysis","volume":"89","author":"Gravel","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3892\/or.2022.8325","article-title":"Bendamustine: a review of pharmacology, clinical use and immunological effects (Review)","volume":"47","author":"Lalic","year":"2022","journal-title":"Oncol. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.7150\/ijms.10656","article-title":"Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database","volume":"12","author":"Mai","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar Chiappini","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40290-020-00329-w","article-title":"US food and drug administration safety advisories and reporting to the adverse event reporting system (FAERS)","volume":"34","author":"Moore","year":"2020","journal-title":"Pharm. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3109\/10428194.2014.915545","article-title":"Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data","volume":"56","author":"Palumbo","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1212\/nxi.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey Sanchez-Gonzalez","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"B30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.medcli.2019.07.010","article-title":"Progressive multifocal leukoencephalopathy in the course of combined therapy with bendamustine and rituximab","volume":"155","author":"Rosas Cancio-Su\u00e1rez","year":"2020","journal-title":"Med. Clin. Barc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"P56","DOI":"10.1186\/2045-7022-4-s3-p56","article-title":"Immunological reactions induced by bendamustine","volume":"4","author":"Sanchez-Gonzalez Bil\u00f2","year":"2014","journal-title":"Clinical&Translational Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-A case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/bloodadvances.202301130","article-title":"Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience","volume":"8","author":"Shotton","year":"2024","journal-title":"Blood Adv."},{"key":"B35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40264-023-01334-z","article-title":"Disproportionality analysis of abemaciclib in the FDA adverse event reporting system: a real-world post-marketing pharmacovigilance assessment","volume":"46","author":"Shu","year":"2023","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3960\/jslrt.21031","article-title":"Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy","volume":"62","author":"Suzuki","year":"2022","journal-title":"J. Clin. Exp. Hematop"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1248\/bpb.b20-00428","article-title":"Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-hodgkin lymphoma","volume":"43","author":"Uchida Trociukas","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"B39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1053\/j.ajkd.2016.07.037","article-title":"Bendamustine-induced nephrogenic diabetes insipidus in a patient with AL amyloidosis","volume":"69","author":"Uwumugambi","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3109\/10428194.2011.649476","article-title":"A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma","volume":"53","author":"Warsch","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"B43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12911-020-1053-z","article-title":"Mining and visualizing high-order directional drug interaction effects using the FAERS database","volume":"20","author":"Yao","year":"2020","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.21873\/anticanres.16120","article-title":"Bendamustine plus rituximab for mantle cell lymphoma: a Korean, multicenter retrospective analysis","volume":"42","author":"Yi","year":"2022","journal-title":"Anticancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","article-title":"A real-world disproportionality analysis of rucaparib: post-marketing pharmacovigilance data","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1182113","DOI":"10.3389\/fphar.2023.1182113","article-title":"Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3109\/10428194.2014.915546","article-title":"Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine","volume":"56","author":"Zimmer","year":"2015","journal-title":"Leuk. Lymphoma"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:58:26Z","timestamp":1715576306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1372401"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1372401","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"article-number":"1372401"}}